Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas
ConclusionsPatients with acSCC are usually very frail and elderly. OS increased over time, with a twofold improvement between periods 1 and 2, whereas progression-free survival (PFS) did not increase. Access to immunotherapy reduced mortality in a majority of patients in period 2. Immunosuppression and advanced age were associated with lower PFS.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Epidemiology | Immunotherapy | Skin Cancer | Squamous Cell Carcinoma | Study